Sign in Sign up for free

Last updated: 21 June 2022 at 6:39am EST

David Milligan Net Worth




The estimated Net Worth of David V Milligan is at least $8.88 Million dollars as of 19 November 2018. David Milligan owns over 10,000 units of Madrigal Pharmaceuticals Inc stock worth over $4,660,000 and over the last 8 years he sold MDGL stock worth over $3,566,800. In addition, he makes $657,500 as Independent Director at Madrigal Pharmaceuticals Inc.

David Milligan MDGL stock SEC Form 4 insiders trading

David has made over 4 trades of the Madrigal Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of MDGL stock worth $2,250,800 on 21 November 2018.

The largest trade he's ever made was selling 20,000 units of Madrigal Pharmaceuticals Inc stock on 21 November 2018 worth over $2,250,800. On average, David trades about 5,455 units every 6 days since 2016. As of 19 November 2018 he still owns at least 20,000 units of Madrigal Pharmaceuticals Inc stock.

You can see the complete history of David Milligan stock trades at the bottom of the page.





David Milligan biography

Dr. David V. Milligan Ph.D. serves as Independent Director of the Company. Previously, Dr. Milligan was a partner at Bay City Capital LLC, a life sciences investment firm, a position he held from 1997 through 2013. From 1979 to 1996, Dr. Milligan served in a variety of roles retiring as Senior Vice President and Chief Scientific Officer at Abbott Laboratories, a publicly-held healthcare products company. Dr. Milligan currently serves as a director of Inspirotech and Minute Molecular Diagnostics, which are privately-held life sciences companies. He is also on the Board of Xoult, a life sciences software company, as well as Ekatra Inc., a company utilizing information technology to monitor and protect valuable assets. From 2016 to 2018 he was a board member for WebLoq Inc, a privately-held information technology security company that is no longer in business. Starting in 1995, Dr. Milligan served as a director of Caliper Life Sciences, a publicly-held pharmaceutical and biotechnology company that was acquired by PerkinElmer Company in 2011, as well as ICOS, a publicly-held pharmaceutical company where he was a board member and later lead director before it was acquired by Eli Lilly in 2008. Dr. Milligan also served as Chairman and a director at Vicuron Pharmaceuticals, Inc., a privately-held biopharmaceutical company from 1997 to 2005 when it was acquired by Pfizer. He was also a director of Reliant Pharmaceuticals, Inc., a privately-held pharmaceutical company from 1999 until acquired by GlaxoSmithKline, in 2007. In addition, he was a director of Pathway Diagnostics Corporation, a privately-held diagnostics company acquired by Quest Diagnostics, Inc., and a director of Maxia Pharmaceuticals, Inc., a privately-held pharmaceutical company acquired by Incyte Corporation, from 1999 to 2003. Dr. Milligan received an A.B. in Chemistry from Princeton University and an M.S. and Ph.D. in Organic Chemistry from the University of Illinois.

What is the salary of David Milligan?

As the Independent Director of Madrigal Pharmaceuticals Inc, the total compensation of David Milligan at Madrigal Pharmaceuticals Inc is $657,500. There are 13 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.



How old is David Milligan?

David Milligan is 79, he's been the Independent Director of Madrigal Pharmaceuticals Inc since 2016. There are no older and 17 younger executives at Madrigal Pharmaceuticals Inc.

What's David Milligan's mailing address?

David's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.

Insiders trading at Madrigal Pharmaceuticals Inc

Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman, and Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.



What does Madrigal Pharmaceuticals Inc do?

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.



What does Madrigal Pharmaceuticals Inc's logo look like?

Madrigal Pharmaceuticals Inc logo

Complete history of David Milligan stock trades at Madrigal Pharmaceuticals Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
21 Nov 2018 MDGL Madrigal Pharmaceuticals Inc David V Milligan
Director
 Sale 20,000 $112.54 $2,250,800
21 Nov 2018
0 ↗
19 Nov 2018 MDGL Madrigal Pharmaceuticals Inc David V Milligan
Director
 Sale 10,000 $131.60 $1,316,000
19 Nov 2018
20,000 ↗
14 Nov 2018 MDGL Madrigal Pharmaceuticals Inc David V Milligan
Director
 Option 10,000 $16.46 $164,600
14 Nov 2018
30,000 ↗
18 Sep 2018 MDGL Madrigal Pharmaceuticals Inc David V Milligan
Director
 Option 20,000 $9.45 $189,000
18 Sep 2018
20,000 ↗


Madrigal Pharmaceuticals Inc executives and stock owners

Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include: